Comerica Bank reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,816 shares of the biopharmaceutical company’s stock after selling 5,643 shares during the quarter. Comerica Bank’s holdings in Alnylam Pharmaceuticals were worth $2,295,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Investment Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $25,000. City Holding Co. purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $30,000. CWM LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 1,571.4% in the 3rd quarter. CWM LLC now owns 585 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 550 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Alnylam Pharmaceuticals by 70.2% in the 2nd quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 259 shares in the last quarter. Finally, Price Wealth Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at about $46,000. Hedge funds and other institutional investors own 93.51% of the company’s stock.

Several brokerages recently weighed in on ALNY. Zacks Investment Research cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 target price for the company. in a report on Wednesday, September 18th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Nomura set a $62.00 target price on Alnylam Pharmaceuticals and gave the company a “sell” rating in a report on Tuesday, October 8th. Stifel Nicolaus set a $116.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, ValuEngine cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $111.50.

ALNY opened at $90.58 on Thursday. The business has a 50 day simple moving average of $84.57 and a two-hundred day simple moving average of $78.09. The firm has a market capitalization of $10.37 billion, a price-to-earnings ratio of -11.97 and a beta of 2.37. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.38 and a quick ratio of 5.22. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $96.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($2.17) by $0.25. The business had revenue of $70.06 million during the quarter, compared to analyst estimates of $57.14 million. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. Alnylam Pharmaceuticals’s quarterly revenue was up 3284.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.56) EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.89 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 58,913 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the completion of the transaction, the president now owns 111,851 shares of the company’s stock, valued at approximately $10,065,471.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Maraganore sold 49,456 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $79.45, for a total value of $3,929,279.20. Following the transaction, the chief executive officer now directly owns 239,449 shares of the company’s stock, valued at approximately $19,024,223.05. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.